scholarly journals Temporal trends in loss of life expectancy after a cancer diagnosis among the Australian population

2020 ◽  
Vol 65 ◽  
pp. 101686
Author(s):  
Kou Kou ◽  
Paramita Dasgupta ◽  
Susanna M. Cramb ◽  
Xue Q. Yu ◽  
Therese M.-L. Andersson ◽  
...  
2021 ◽  
Vol 50 (Supplement_1) ◽  
Author(s):  
Peter Baade ◽  
Kou Kou ◽  
Paramita Dasgupta ◽  
Susanna Cramb ◽  
Xue Qin Yu

Abstract Background While relative survival is commonly used to describe cancer prognosis, its interpretation remains confusing. Alternative measures provide additional insights into the survival experience of Australian cancer patients. Methods Population-based cohort of over 2 million Australians diagnosed with 19 types of primary invasive cancer from 1982 to 2014 with mortality follow-up to 31 December 2015. Flexible parametric survival models were used to estimate loss of life expectancy, avoidable cancer deaths, crude survival, probability of cure and survival of uncured population for cancers diagnosed in Australia. Results There has been an overall decrease in the loss of life expectancy caused by a cancer diagnosis. Australians diagnosed in 2014 will gain an extra 432,588 life years due to the improvement in relative survival since 1982. Similarly, 29% (females) and 40% (males) of expected cancer deaths among the 2005-2014 cohort will be avoided compared to the 1985-1994 cohort. While the 10- year crude probability of cancer deaths decreased over time, patterns varied by cancer type. The crude probability of competing deaths increased with age. Between 1982 and 2009, the cure proportion increased significantly for all cancers. Conclusion Alternative measures of survival may help communicate the reducing impact that a cancer diagnosis has on average life expectancy. Key messages The growing number of Australian cancer survivors can pose emerging challenges to these patients, their caregivers, medical professionals and health-care systems in accessing or providing evidence-based survivorship and psychosocial care after a cancer diagnosis.


2019 ◽  
Vol 114 (9) ◽  
pp. 1478-1487 ◽  
Author(s):  
Kunlin Xie ◽  
Chien-Hua Chen ◽  
Shan-Pou Tsai ◽  
Po-Jung Lu ◽  
Hong Wu ◽  
...  

2020 ◽  
Vol 126 ◽  
pp. 18-26 ◽  
Author(s):  
Andrew Morton ◽  
Michael Williams ◽  
Marlon Perera ◽  
Patrick E. Teloken ◽  
Peter Donato ◽  
...  

2017 ◽  
Vol 117 (9) ◽  
pp. 1419-1426 ◽  
Author(s):  
Elisavet Syriopoulou ◽  
Hannah Bower ◽  
Therese M-L Andersson ◽  
Paul C Lambert ◽  
Mark J Rutherford

2020 ◽  
Author(s):  
Michael Drozd ◽  
Samuel D Relton ◽  
Andrew MN Walker ◽  
Thomas Slater ◽  
John Gierula ◽  
...  

AbstractBackgroundEstimating survival can aid care planning, but the use of absolute survival projections can be challenging for patients and clinicians to contextualize. We aimed to define how heart failure and its major comorbidities contribute to loss of actuarially predicted life expectancy.MethodsWe conducted an observational cohort study of 1794 adults with stable chronic heart failure and reduced left ventricular ejection fraction, recruited from cardiology outpatient departments of 4 United Kingdom (UK) hospitals. Data from an 11-year maximum (5-year median) follow-up period (999 deaths) was used to define how heart failure and its major comorbidities impact upon survival, relative to an age-sex matched control UK population, using a relative survival framework.ResultsAfter 10 years, mortality in the reference control population was 29%. In people with heart failure, this increased by an additional 37% (95% confidence interval 34-40%), equating to an additional 2.2-years of lost life, or a 2.4-fold (2.2-2.5) excess loss of life. This excess was greater in men than women (2.4 years [2.2-2.7] versus 1.6 years [1.2-2.0]; p<0.001). In patients without major comorbidity, men still experienced excess loss of life, whilst women experienced less and were non-significantly different from the reference population (1 year [0.6-1.5] versus 0.4 years [-0.3-1]; p<0.001). Accrual of comorbidity was associated with substantial increases in excess loss of life, particularly for chronic kidney and lung disease.ConclusionsComorbidity accounts for the majority of lost life expectancy in people with heart failure. Women, but not men, without comorbidity experience survival close to reference controls.


Sign in / Sign up

Export Citation Format

Share Document